Half a million US children have been diagnosed with Covid-19, according to the American Academy of Pediatrics and the Children’s Hospital Association. The news came on the same day that AstraZeneca said it weas pausing its test of a potential vaccine.

The groups said 70,630 new child cases were reported from August 20 through September 3. This is a 16% increase in child cases over two weeks, bringing up the total to at least 513,415 cases, the groups said in their weekly report on pediatric coronavirus cases.

“These numbers are a chilling reminder of why we need to take this virus seriously,” American Academy of Pediatrics President Dr. Sally Goza said in a news release. “While much remains unknown about COVID-19, we do know that the spread among children reflects what is happening in the broader communities,” she added.

“A disproportionate number of cases are reported in Black and Hispanic children and in places where there is high poverty. We must work harder to address societal inequities that contribute to these disparities.”

Children represent nearly 10% of all reported cases in the US, according to the report. The child cases are likely underreported because the tally relies on state data that is inconsistently collected.

Potential COVID-19 treatment has ‘clear and compelling’ effect, says biopharma with US HQ in Raleigh

“This rapid rise in positive cases occurred over the summer, and as the weather cools, we know people will spend more time indoors,” Dr. Sean O’Leary, the vice chair of the AAP Committee on Infectious Diseases, said in a news release.

“Now we are heading into flu season. We must take this seriously and implement the public health measures we know can help,” O’Leary added.

AstraZeneca explains pause

AstraZeneca paused global trials of its coronavirus vaccine because of an unexplained illness in one of the volunteers.

It’s a standard precaution in vaccine trials that is meant to ensure experimental vaccines don’t cause serious reactions among participants.

“As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process triggered a pause to vaccination to allow review of safety data,” the company said in a statement sent to CNN.

GSK, Pfizer, other pharma CEOs pledge COVID-19 vaccines will be safe, effective

The company is testing its vaccine, called the Oxford vaccine because it was developed with Britain’s University of Oxford, in the United States as well as the UK, Latin America, Asia, Europe and Africa.

“This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials,” the statement added.

LabCorp launching test to detect both COVID-19 and flu

“In large trials, illnesses will happen by chance but must be independently reviewed to check this carefully. We are working to expedite the review of the single event to minimize any potential impact on the trial timeline. We are committed to the safety of our participants and the highest standards of conduct in our trials.”

Earlier Tuesday, AstraZeneca joined eight other companies in signing a pledge promising they would not seek premature government approval for any coronavirus vaccine. They promised they would wait until they had adequate data showing any potential vaccine worked safely.

“We, the undersigned biopharmaceutical companies, want to make clear our on-going commitment to developing and testing potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles,” the statement read. It was signed by the CEOs of AstraZeneca, BioNTech GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer and Sanofi.

“We believe this pledge will help ensure public confidence in the rigorous scientific and regulatory process by which COVID-19 vaccines are evaluated and may ultimately be approved,” they added.

The AstraZeneca vaccine is one of three coronavirus vaccines in late-stage, Phase 3 trials in the US. A Data and Safety Monitoring Board (DSMB) usually monitors trials for adverse events and can order a pause or halt a trial, but AstraZeneca did not say who had stopped the trial.

Common adverse events in vaccine trials include fever, headache, soreness at the injection site and muscle pain.

Regulators and companies alike have been working to ensure people trust in the vaccine authorization process. The US Food and Drug Administration must give either emergency use authorization or full approval to any vaccine before it can be distributed in the US.

President Trump has said repeatedly he thinks at least one of the vaccines could be ready before Election Day on November 3. Most groups working on the vaccine say that is extremely unlikely but Biontech CEO and co-founder Ugur Sahin told CNN earlier Tuesday he believes the vaccine his company is developing with Pfizer could be ready for regulatory approval by mid-October.

Dr. Tony Fauci, director of the National Institute of Allergy and Infectious Diseases, has said it’s technically possible that if a DSMB saw strong evidence a vaccine was working before a trial was completed, it cold recommend a halt to the trial so more people could get the vaccine. But Fauci sad this was unlikely to happen before December.

However, discussions about early authorizations and reports about White House pressure to speed along a vaccine have worried the public, as well as former FDA officials. Former FDA commissioner Dr. Robert Califf told CNN last week he was concerned even before Covid-19 that Trump would pressure the FDA to make decisions he wanted.

“One of the things that’s had me on pins and needles the last four years is literally Trump could do this with any drug or device or vaccine anytime he wants to,” said Califf, who was commissioner from January 2016 through January 2018.

Fauci and FDA Commissioner Dr. Stephen Hahn have said they would not cave into political interference.